Return to Clinical Trials Search Results

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (MIRANDA)

PRIMARY OUTCOME MEASURE Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not considered appropriate]).-OVER 52 WEEKS Multiple Secondary Endpoints -Please refer to Protocol for Secondary Endpoints. due to limited space here.

PRIMARY OUTCOME MEASURE Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not considered appropriate]).-OVER 52 WEEKS Multiple Secondary Endpoints -Please refer to Protocol for Secondary Endpoints. due to limited space here.